Maxolon to Improve Breastmilk Supply in Diabetic Women: a Randomised Controlled Trial

Metoclopramide to Improve Lactogenesis II in Diabetic Women: a Randomized Controlled Trial

Early use of oral maxalon can hasten and improve the establishment of breastfeeding in diabetic mothers after preterm and term deliveries.

Maxolon promotes breastfeeding by working on the central nervous system which increases the milk producing hormone, prolactin which in turn helps to increase the milk supply for breastfeeding. Successful early breastfeeding establishment is important for continued breastfeeding.

The study aims to determine the breastfeeding initiation and duration rate of a cohort of pregnant women with gestational diabetes(diet-controlled) and insulin dependent and pre-existing diabetes, assess the impact of a post natally administered galactogogue, metoclopramide on the milk volume production and timing of lactogenesis II in diabetic women on diet control and insulin and determine the prolactin response to lactation among diabetic women on diet control and insulin.

Inclusion Criteria:

• All pregnant women with pregestational or gestational diabetes under diet or insulin control

Exclusion Criteria:

• Patient who have epilepsy or on anti-seizure medications,
• Patients who have a history of significant depression or are on antidepressant drugs
• Patients who have pheochromocytoma or uncontrolled hypertension
• Patients who have intestinal bleeding or obstruction
• Patient with known allergy or prior reaction to metoclopramide
• Patient with HIV infection
• Current pregnancy complicated by fetal congenital anomalies and multiple fetuses